The study involved 126 participants aged 18 to 70, all of whom had acute spinal cord injuries in the neck region, resulting in tetraplegia (affecting arm and hand functions). Participants were divided into two groups:
- Treatment group: 78 individuals received six injections of NG 101 directly into the spinal canal
- Placebo group: 48 individuals received placebo injections
The researchers have systematically evaluated motor function recovery in hand-arm muscles, vital for daily living in tetraplegic patients. Six months post-treatment, outcomes were compared between treated patients and those receiving the placebo.
The treatment showed no effect on motor recovery in patients with complete spinal cord injuries. However, for those with incomplete injuries, it led to significant gains in voluntary muscle activation and greater independence in daily activities. The antibody therapy was well tolerated, with no side effects linked to the treatment. This progress highlights the success of years of antibody research spearheaded by Balgrist University Hospital.
MEDICA-tradefair.com; Source: Heidelberg University Hospital
